| Document Date: 2008-09-18 21:56:16
Open Document File Size: 24,64 KBShare Result on Facebook
City SOUTH SAN FRANCISCO / TOKYO / / Company Pneumonia / cSSSI / Astellas Pharma Inc. / GlaxoSmithKline / Theravance Inc. / MRSA / Yamanouchi Pharmaceutical Co. Ltd. / Fujisawa Pharmaceutical Co. Ltd. / / Country Japan / United States / / Currency USD / / Event Business Partnership / M&A / FDA Phase / Funding / Conference Call / / Facility Astellas’ pipeline / / IndustryTerm pharmaceutical / mega pharmaceutical / treatment of infectious disease / biopharmaceutical / pharmaceutical market / manufacturing / pharmaceutical products / / MedicalCondition skin and skin structure infections ( csssi ) / infections / gastrointestinal disorders / bacterial infections / Hospital-Acquired Pneumonia / serious Gram-positive infections / respiratory disease / infectious disease / / Person Steven Barriere / Toichi Takenaka / Rick E Winningham / / / Position Chief Executive Officer / President and Chief Executive Officer / / Product Telavancin / cSSSI / TD-1792 / / ProvinceOrState California / / Technology anti-infectives / drug discovery / / URL www.astellas.com / www.theravance.com / /
SocialTag |
Theravance and Astellas to Collaborate on Telavancin, Investigational Antibiotic for Serious Infections SOUTH SAN FRANCISCO, CA and TOKYO, JAPAN/ November 7, [removed]Theravance, Inc., and Astellas Pharma Inc. announced t